Clinical Trials Logo

Soft Tissue Neoplasms clinical trials

View clinical trials related to Soft Tissue Neoplasms.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03867188 Terminated - Soft Tissue Sarcoma Clinical Trials

Liposomal Bupivacaine (Exparel) in Sarcomas

Start date: January 14, 2019
Phase: Early Phase 1
Study type: Interventional

The purpose of this research is to study a medication called liposomal bupivacaine (EXPAREL®). Study doctors want to see if it is safe, if it can reduce pain after surgery, and the study doctor want to study its use after the removal a soft tissue tumor called a sarcoma

NCT ID: NCT03630601 Terminated - Sarcoma Clinical Trials

Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer, Sarcoma, Skin Cancer, or Soft Tissue Malignancy and Healthy Volunteers

Start date: June 28, 2018
Phase: N/A
Study type: Interventional

This pilot trial studies how well photoacoustic imaging works in diagnosing changes in tumors in participants with breast cancer, sarcoma, skin cancer, or soft tissue malignancy and healthy volunteers. Photoacoustic imaging is a low-risk imaging method that provides information about the oxygenation of tissues using a combination of light and ultrasound techniques. Photoacoustic imaging uses a signal from hemoglobin to provide information on blood flow and oxygen levels, and it may be helpful in determining changes in tumors after chemotherapy or radiation treatment.

NCT ID: NCT02775799 Terminated - Neoplasms Clinical Trials

National Swiss Sarcoma Cohort Study

SwissSARCOS
Start date: April 2015
Phase:
Study type: Observational [Patient Registry]

Registration of all sarcoma patients treated at a specialized sarcoma center in Switzerland.

NCT ID: NCT02602067 Terminated - Clinical trials for Lymphoma, Non-Hodgkin

131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients

Tenatumomab
Start date: November 2015
Phase: Phase 1
Study type: Interventional

Tenatumomab is a Sigma-Tau developed new anti-Tenascin antibody. It is a murine monoclonal antibody directed towards Tenascin-C. By means of this antibody, Tenascin-C expression was studied on a commercial tissue array slides each carrying malignant breast, colorectal, lung, ovarian or B and T cell Non-Hodgkin Limphoma tissue sections. All these cancers type showed positivity to Tenascin-C between the 64% and 13.3%. Consequently, Sigma-tau is exploring the use of the 131I-labeled Tenatumomab for anti-cancer radioimmunotherapy.

NCT ID: NCT01965002 Terminated - Clinical trials for Soft Tissue Neoplasms

Feasibility of ExAblate MRI Guided High Intensity Focused Ultrasound Tx of Soft Tissue Tumors

Start date: May 2014
Phase: N/A
Study type: Interventional

The goal of this project is to evaluate the safety and preliminary efficacy of ExAblate magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) surgery in the treatment of soft tissue tumors of the extremities.